Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AVLN
Strong SellSinkerAvalyn Pharma Inc. · Healthcare · United States · $1.5B · Avg Vol: $6M/d
COMPANY DESCRIPTION
Avalyn Pharma Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for the treatment of interstitial lung diseases, including idiopathic pulmonary fibrosis. The company's competitive advantage lies in its proprietary aerosolized formulations designed to deliver therapeutic agents directly to the lungs, minimizing systemic side effects. As a niche player in pulmonary medicine, Avalyn aims to improve patient outcomes by optimizing drug delivery for severe respiratory conditions.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | — | — | — |
| EPS | -1.19 | -2.04 | -2.33 | -1.94 | -1.90 | — |
| Shares | 41.8M | 41.8M | 44.3M | — | — | — |
| Debt | 0 | 1.7M | — | — | — | — |
| Equity | -174.5M | -238.7M | — | — | — | — |
| Op CF | -48.4M | -81.5M | -97.5M | — | — | — |
| Inv CF | -91.5M | 10.1M | — | — | — | — |
| Fin CF | 89.0K | 99.8M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVLN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc.(you) | $1.5B | 10 | Strong Sell |
| LTGO | Latigo Biotherapeutics, Inc. | $1.5B | 8 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $1.4B | 11 | Strong Sell |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 7 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.5B | 7 | Strong Sell |
| NVAX | Novavax, Inc. | $1.5B | 14 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.3B | 10 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 11 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.5B | 6 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%